Faran Shimi, a subsidiary of Golrang Pharmaceutical Group, has announced the official launch of the drug Macitentan in the country’s pharmaceutical market, as part of its efforts to complete its respiratory therapeutics product portfolio.
According to the Public Relations Department of Golrang Pharmaceutical Group, this drug—marketed under the brand name Opsitentan—is used for the treatment of Pulmonary Arterial Hypertension (PAH).
The introduction of Opsitentan, alongside Farantan (Bosentan), aims to complete the PAH treatment portfolio and increase patient access to effective therapies.
Macitentan is an oral endothelin receptor antagonist (ERA) that reduces pulmonary vascular pressure and improves oxygenation in the body by inhibiting the effects of endothelin-1.
Opsitentan is produced and marketed by Faran Shimi Pharmaceutical Company as a 10 mg oral tablet, supplied in 30-tablet packages.
